{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T03:00:44Z","timestamp":1755226844503,"version":"3.43.0"},"reference-count":26,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences","award":["NCRC2022003"],"award-info":[{"award-number":["NCRC2022003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,3]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Residual thrombosis risk is an important contributor to ischaemic events in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Although previous studies have shown that rivaroxaban 2.5 mg two times per day in ACS patients with high ischaemic risk can significantly reduce the risk of ischaemic recurrence and mortality, individualised treatment with low-dose rivaroxaban is still rare. Using D-dimer and PARIS (Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients) coronary thrombosis risk score to identify ACS patients at high ischaemic risk, we aim to investigate whether 3-month low-dose rivaroxaban therapy on the basis of dual antiplatelet therapy (DAPT) could result in reduced ischaemic events without increasing bleeding.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>\nThis study is a multicentre, prospective, open-label, randomised controlled trial involving 3944 ACS patients undergoing PCI from more than 40 tertiary hospitals in China (ClinicalTrials.gov\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05638867\">NCT05638867<\/jats:ext-link>\n). Patients with PARIS coronary thrombosis score =3 or D-dimer =0.28 \u00b5g\/mL will be 1:1 randomised to the experimental group (rivaroxaban 2.5 mg two times per day for 3 months on the basis of 1 year standard DAPT) or the control group (1 year standard DAPT only). The primary endpoint of this study is major adverse cardiovascular and cerebrovascular events (MACCE), a composite of death, myocardial infarction, unplanned ischaemia-driven revascularisation and systemic embolic events. The safety endpoint is Bleeding Academic Research Consortium (BARC) type 3 and 5 bleeding events.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>Institutional Review Board (IRB) approval by the Ethics Committee of Fuwai Hospital was obtained on 22 April 2023 (Approval No. 2023\u20131980). The investigators will have access to the final dataset. Trial results will be made public through publication in professional journals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05638867\">NCT05638867<\/jats:ext-link>\n.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090126","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:11:55Z","timestamp":1747732315000},"page":"e090126","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["PARIS coronary thrombosis risk score combined with D-dimer to guide new oral anticoagulant antithrombotic therapy in patients with acute coronary syndrome after percutaneous coronary intervention: study protocol for the PRIDE-ACS trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05638867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05638867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05638867","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sida","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ce","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-5103","authenticated-orcid":false,"given":"Jin-qing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2025051521551025000_15.5.e090126.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.058"},{"key":"2025051521551025000_15.5.e090126.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"2025051521551025000_15.5.e090126.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"2025051521551025000_15.5.e090126.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"2025051521551025000_15.5.e090126.5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ajh.25482","article-title":"The D-dimer assay","volume":"94","author":"Johnson","year":"2019","journal-title":"Am J Hematol"},{"key":"2025051521551025000_15.5.e090126.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07813-3"},{"key":"2025051521551025000_15.5.e090126.7","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619853638","article-title":"Prognostic value of the PARIS thrombotic risk score for 2-year mortality after percutaneous coronary intervention","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025051521551025000_15.5.e090126.8","doi-asserted-by":"crossref","unstructured":"Jia S , Deshan Y , Song Y , et al . Impact of D-Dimer on the Prognostic Value of PARIS Thrombosis Risk Score in Acute Coronary Syndrome Patients Undergoing PCI: From a Large Prospective Cohort Study. Catheter Cardiovasc Interv 2025. doi:10.1002\/ccd.31526","DOI":"10.1002\/ccd.31526"},{"key":"2025051521551025000_15.5.e090126.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030190"},{"key":"2025051521551025000_15.5.e090126.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594"},{"key":"2025051521551025000_15.5.e090126.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30397-5"},{"key":"2025051521551025000_15.5.e090126.12","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320904302","article-title":"D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention","volume":"11","author":"Zhao","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"2025051521551025000_15.5.e090126.13","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1093\/eurheartj\/ehz394","article-title":"Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease","volume":"40","author":"Zhang","year":"2019","journal-title":"Eur Heart J"},{"key":"2025051521551025000_15.5.e090126.14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1253\/circj.CJ-20-0300","article-title":"Comparison of percutaneous coronary intervention, coronary artery bypass grafting and medical therapy in Non-ST elevation acute coronary syndrome patients with 3-vessel disease","volume":"84","author":"Jia","year":"2020","journal-title":"Circ J"},{"key":"2025051521551025000_15.5.e090126.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"2025051521551025000_15.5.e090126.16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J"},{"key":"2025051521551025000_15.5.e090126.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817083"},{"key":"2025051521551025000_15.5.e090126.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454"},{"key":"2025051521551025000_15.5.e090126.19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijcard.2016.04.044","article-title":"Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea acute myocardial infarction registry-national institute of health","volume":"215","author":"Park","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025051521551025000_15.5.e090126.20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0112"},{"key":"2025051521551025000_15.5.e090126.21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FJC.0000000000001225","article-title":"Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Ma","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025051521551025000_15.5.e090126.22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"2025051521551025000_15.5.e090126.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029901"},{"key":"2025051521551025000_15.5.e090126.24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.amjcard.2018.07.032","article-title":"D-dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)","volume":"122","author":"AlKhalfan","year":"2018","journal-title":"Am J Cardiol"},{"key":"2025051521551025000_15.5.e090126.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.064"},{"key":"2025051521551025000_15.5.e090126.26","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.4103\/0366-6999.245263","article-title":"Validation of predictive value of patterns of nonadherence to antiplatelet regimen in stented patients thrombotic risk score in Chinese population undergoing percutaneous coronary intervention","volume":"131","author":"Zhao","year":"2018","journal-title":"Chin Med J (Engl)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:12:11Z","timestamp":1747732331000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2024-090126"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090126","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}